DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Tauroursodeoxycholic acid is an investigational drug.
There have been 22 clinical trials for Tauroursodeoxycholic acid. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2012.
The most common disease conditions in clinical trials are Sclerosis, Amyloidosis, and Motor Neuron Disease. The leading clinical trial sponsors are Washington University School of Medicine, Beijing Trendful Kangjian Medical Information Consulting Limited Company, and IRCCS Policlinico S. Matteo.
There are three hundred and thirty-eight US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Tauroursodeoxycholic acid
|The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.||The First Affiliated Hospital with Nanjing Medical University||Early Phase 1|
|Targeting ER Stress in Vascular Dysfunction||Colorado State University||Early Phase 1|
|TUDCA as a Therapy for Ulcerative Colitis (UC)||Crohn's and Colitis Foundation||Phase 1|
Top disease conditions for Tauroursodeoxycholic acid
Top clinical trial sponsors for Tauroursodeoxycholic acid
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tauroursodeoxycholic acid||Get Started Free||Measurement method for human pancreatic lipase activity||ASAHI KASEI PHARMA CORPORATION (Tokyo, JP)||Get Started Free|
|Tauroursodeoxycholic acid||Get Started Free||17-hydroxyprogesterone ester-containing oral compositions and related methods||Lipocine Inc. (Salt Lake City, UT)||Get Started Free|
|Tauroursodeoxycholic acid||Get Started Free||Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use||Vivus, Inc. (Campbell, CA)||Get Started Free|
|Tauroursodeoxycholic acid||Get Started Free||Animal model of nash-induced hepatocellular carcinoma and methods for developing specific therapeutics||The Regents of the University of California (Oakland, CA)||Get Started Free|
|Tauroursodeoxycholic acid||Get Started Free||Methods and systems for determining autism spectrum disorder risk||Laboratory Corporation of America Holdings (Burlington, NC)||Get Started Free|
|Tauroursodeoxycholic acid||Get Started Free||Therapy for transthyretin-associated amyloidosis||SOM Innovation Biotech, S.L. (Barcelona, ES)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Tauroursodeoxycholic acid||China||CN105164273||2033-04-18||Get Started Free|
|Tauroursodeoxycholic acid||European Patent Office||EP2987867||2033-04-18||Get Started Free|
|Tauroursodeoxycholic acid||Spain||ES2654437||2033-04-18||Get Started Free|
|Tauroursodeoxycholic acid||Japan||JP6064041||2033-04-18||Get Started Free|
|Tauroursodeoxycholic acid||Japan||JPWO2014171505||2033-04-18||Get Started Free|
|Tauroursodeoxycholic acid||South Korea||KR101811930||2033-04-18||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|